ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

GNMSF Genmab A S (PK)

284.63
12.58 (4.62%)
Last Updated: 18:10:01
Delayed by 15 minutes
Share Name Share Symbol Market Type
Genmab A S (PK) USOTC:GNMSF OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  12.58 4.62% 284.63 270.75 288.10 284.63 274.22 274.22 104 18:10:01

Report of Foreign Issuer (6-k)

31/03/2020 2:39pm

Edgar (US Regulatory)


 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549



FORM 6-K


REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16

OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF MARCH 2020


COMMISSION FILE NUMBER 001-38976 

Genmab A/S
(Exact name of Registrant as specified in its charter)

Kalvebod Brygge 43

1560 Copenhagen V

Denmark

+45 70 20 27 28
(Address of principal executive offices)


Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F.

Form 20‑F       Form 40‑F 

Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1)

Yes       No     

Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7)

Yes       No     

This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statements on Form S-8 (File No. 333-232693) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

 

 

 

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

 

GENMAB A/S

 

 

 

 

BY:

/s/ Anthony Pagano

 

 

Name: Anthony Pagano

 

 

Title: Executive Vice President & Chief Financial Officer

 

DATE: March 31, 2020

EXHIBIT INDEX

 

 

 

Exhibit

Description of Exhibit

 

 

3.1

Articles of Association

 

 

 

 

1 Year Genmab A S (PK) Chart

1 Year Genmab A S (PK) Chart

1 Month Genmab A S (PK) Chart

1 Month Genmab A S (PK) Chart

Your Recent History

Delayed Upgrade Clock